Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Manidipine is a dihydropyridine calcium channel blocker used primarily for the treatment of hypertension. It acts by selectively inhibiting L-type and T-type voltage-dependent calcium channels in vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Its selectivity for vascular tissue over cardiac tissue minimizes cardiac side effects at therapeutic doses. In addition to its antihypertensive effect, manidipine increases renal blood flow and promotes natriuresis (excretion of sodium), which may further contribute to its blood pressure-lowering action. The drug has a prolonged duration of action due to high receptor affinity and slow dissociation from binding sites[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on manidipine.